Format

Send to

Choose Destination

See 1 citation found by title matching your search:

See comment in PubMed Commons below
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6973-8. doi: 10.1073/pnas.1221609110. Epub 2013 Apr 1.

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.

Author information

1
New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA.

Abstract

T cells expressing antigen-specific T-cell receptors (TCRs) can mediate effective tumor regression, but they often also are accompanied by autoimmune responses. To determine the TCR affinity threshold defining the optimal balance between effective antitumor activity and autoimmunity in vivo, we used a unique self-antigen system comprising seven human melanoma gp100(209-217)-specific TCRs spanning physiological affinities (1-100 μM). We found that in vitro and in vivo T-cell responses are determined by TCR affinity, except in one case that was compensated by substantial CD8 involvement. Strikingly, we found that T-cell antitumor activity and autoimmunity are closely coupled but plateau at a defined TCR affinity of 10 µM, likely due to diminished contribution of TCR affinity to avidity above the threshold. Together, these results suggest that a relatively low-affinity threshold is necessary for the immune system to avoid self-damage, given the close relationship between antitumor activity and autoimmunity. The low threshold, in turn, indicates that adoptive T-cell therapy treatment strategies using in vitro-generated high-affinity TCRs do not necessarily improve efficacy.

PMID:
23576742
PMCID:
PMC3637771
DOI:
10.1073/pnas.1221609110
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center